Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025

Corsair Pharma, Inc. is a private biopharmaceutical company. The company has just announced the successful completion of a preclinical program for Its treprostinil Prodrug Transdermal System and its plans to start a Phase 1 trial in Q2 of 2025. The Corsair transdermal patch is intended to provide steady and continuous blood levels of the prostacyclin […]

Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025 Read Post »